Literature DB >> 2014535

Risk factors for obliterative bronchiolitis in heart-lung transplant recipients.

J P Scott1, T W Higenbottam, L Sharples, C A Clelland, R L Smyth, S Stewart, J Wallwork.   

Abstract

Obliterative bronchiolitis is the major cause of death of long-term survivors of heart-lung transplantation. Of our first 75 patients who have received heart-lung transplantation, 38 have been followed for a year or longer. Eight patients developed clinical evidence of obliterative bronchiolitis within 15 months of transplantation, of whom four died with postmortem confirmation of extensive obliterative bronchiolitis, interstitial and pleural fibrosis, and vascular sclerosis in the heart and lungs. One further patient died before one year after chronic rejection. All nine patients had evidence on transbronchial biopsy of submucosal fibrosis and vascular sclerosis. Twelve of our remaining patients have shown similar areas of lung fibrosis on transbronchial biopsy, and the other eighteen are well and without fibrosis on transbronchial biopsy. Studies of the 274 biopsies obtained from 38 patients confirmed rejection on 182 occasions with more frequent, more persistent, and more severe rejection in the chronic rejection group than in the without-fibrosis or lung fibrosis groups. Opportunistic infection resulted in pneumonia on 19 occasions, and were most commonly found in lung fibrosis patients. We conclude that obliterative bronchiolitis is the likely outcome in patients with early, poorly controlled, severe rejection.

Entities:  

Mesh:

Year:  1991        PMID: 2014535     DOI: 10.1097/00007890-199104000-00015

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  13 in total

Review 1.  New immunosuppressive drugs and lung transplantation: last or least?

Authors:  J W van den Berg; D S Postma; G H Koëter; W van der Bij
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

2.  BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS.

Authors: 
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

Review 3.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 4.  Heart-lung transplantation for end-stage respiratory disease in cystic fibrosis patients.

Authors:  J P Scott; C Dennis; P Mullins
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

5.  Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker.

Authors:  Damien J LaPar; Marie D Burdick; Abbas Emaminia; David A Harris; Brett A Strieter; Ling Liu; Mark Robbins; Irving L Kron; Robert M Strieter; Christine L Lau
Journal:  Ann Thorac Surg       Date:  2011-08       Impact factor: 4.330

Review 6.  Heart-lung transplantation: pediatric indications and outcomes.

Authors:  Jonathan E Spahr; Shawn C West
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

7.  Surveillance bronchoscopy in children during the first year after lung transplantation: Is it worth it?

Authors:  C Benden; O Harpur-Sinclair; A S Ranasinghe; J C Hartley; M J Elliott; P Aurora
Journal:  Thorax       Date:  2006-08-23       Impact factor: 9.139

Review 8.  Overview of lung transplantation.

Authors:  Marlyn S Woo
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

9.  IL-16 in the airways of lung allograft recipients with acute rejection or obliterative bronchiolitis.

Authors:  M Laan; A Lindén; G C Riise
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

10.  Coexpression of aspartic proteinases and human leukocyte antigen-DR in human transplanted lung.

Authors:  E Arbustini; P Morbini; M Diegoli; M Grasso; R Fasani; P Vitulo; R Fiocca; P Cremaschi; G Volpato; L Martinelli
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.